Neoplasms in the region of the pituitary fossa

Published on 20/03/2015 by admin

Filed under Pathology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2983 times

44

Neoplasms in the region of the pituitary fossa

Neoplasms in the region of the pituitary fossa may arise in the pituitary gland itself, the sphenoid bone that surrounds the fossa, or the suprasellar region (Figs 44.1, 44.2). Structures in the suprasellar region and adjacent to the pituitary fossa include the hypothalamus, optic chiasm, nasal sinuses, and cavernous sinuses and their contents.

Common neoplasms in this region are:

Uncommon neoplasms in this region are:

Other neoplasms are rare.

The pituitary gland weighs about 600 mg and consists mainly of the adenohypophysis (anterior lobe) and the neurohypophysis (posterior lobe) (Figs 44.344.6); the pars intermedia is poorly developed in man.

Adenomas are the commonest neoplasms in the pituitary gland and are derived from cells in the adenohypophysis. Neoplasms of neurohypophyseal origin are very rare.

PITUITARY ADENOMAS

Pituitary adenomas are derived from secretory cells in the adenohypophysis. Some adenomas secrete peptides in an unregulated manner and may therefore produce abnormal endocrine effects in addition to causing mass effects in the region of the pituitary fossa (Fig. 44.7).

MACROSCOPIC APPEARANCES

Pituitary adenomas are soft and have a beige or cream color. Discussion between the neurosurgeon and pathologist at the time of operation sometimes raises the possibility of an alternative diagnosis (e.g. a tough mass is more likely to be a meningioma).

By convention, macroadenomas and microadenomas have diameters above and below 10 mm, respectively. Most microadenomas diagnosed in life are ACTH-cell adenomas and PRL-cell adenomas presenting early with endocrine effects. Histopathologic assessment of surgically treated microadenomas requires a thorough examination of all submitted tissue.

MICROSCOPIC APPEARANCES

image PITUITARY ADENOMAS

image The commonest neoplasms in the region of the pituitary fossa, and represent 10–15% of intracranial neoplasms.

image Have an incidence ranging from 1–15/100 000 in different series.

image Most common in the third to sixth decades.

image Show a female:male ratio of approximately 2:1 in younger patients.

image May be an incidental finding in approximately 10% of elderly people according to some necropsy series (40% of these neoplasms are prolactinomas).

image May present with the effects of increased peptide production (i.e. acromegaly or gigantism due to excess GH, Cushing syndrome due to excess ACTH, amenorrhea, galactorrhea, or impotence due to excess PRL, hyperthyroidism due to excess TSH).

image May present with mass effects (i.e. headache, compression of the optic chiasm, (other) cranial nerve palsies, compression of the othalamus, hypopituitarism, pituitary infarction). Pituitary peptide deficiencies preceding complete hypopituitarism tend to occur in sequence (i.e. GH → FSH/LH → TSH → ACTH).

image Can compress the pituitary stalk and thereby compromise transport of PRL inhibitory factor (dopamine) to the adenohypophysis, resulting in an elevated PRL level (‘stalk effect’), but PRL concentrations seldom exceed 200 mg/L in these circumstances.

image May present acutely with mass effects when they undergo infarction or hemorrhage.

The histology of pituitary adenomas is varied (Table 44.1). Many adenomas consist of small, oval, or polyhedral cells. These may be arranged in monotonous sheets or show a variety of acinar, papillary, trabecular, or other patterns (Figs 44.944.11). The nuclei of neoplastic cells are generally round or oval and contain the stippled chromatin typical of neuroendocrine neoplasms. Tiny nucleoli may be evident. Cytologic pleomorphism and mitotic figures may be present, but do not necessarily signify aggressive biologic behavior (Fig. 44.12). Invasion of local structures (Fig. 44.13), particularly the dura, is not infrequent, even by adenomas with bland cytologic features.

Dystrophic calcification and eosinophilic (amyloid) bodies are strongly associated with prolactinomas (Fig. 44.14). Long-term treatment of prolactinomas with bromocriptine before surgical resection produces fibrosis.

Crooke’s hyaline change describes the development of a zone of glassy agranular cytoplasm around the nuclei of non-adenomatous corticotrophs in patients with elevated corticosteroid concentrations due to an ACTH-cell adenoma, a systemic ACTH-producing neoplasm, an adrenal neoplasm or exogenous corticosteroid administration (Fig. 44.15). This appearance results from a massive accumulation of keratin microfilaments.

A small proportion of null-cell adenomas comprises oncocytomas (Fig. 44.16). The (arbitrary) ultrastructural criterion for a diagnosis of oncocytoma is that more than 10% of the cell volume must be occupied by mitochondria. ACTH-cell adenomas occasionally show oncocytic change.

Immunohistochemistry to assess the production of peptide hormones (Figs 44.1744.20, Table 44.2) is used with electron microscopy (Figs 44.21, 44.22) to classify pituitary adenomas. The various pituitary trichrome stains are useful for demonstrating normal adenohypophysis, but of limited value for distinguishing different types of adenoma. Immunolabeling of a hormone in adenoma cells does not necessarily signify that it is secreted in a physiologically active form. This is exemplified by the patchy and usually weak labeling of cells in some adenomas with FSH, LH, TSH or α subunit antibodies. Pituitary adenomas label with antibodies tosynaptophysin, chromogranin-A, and low molecular weight cytokeratins (Table 44.3).

In some reports, invasive adenomas and adenomas that recur have a higher growth fraction as assessed by Ki-67 antibodies.

A diagnosis of pituitary carcinoma requires evidence of metastasis; either discontinuous spread of neoplasm within the CNS or spread outside the CNS. Pituitary carcinomas can produce any pituitary peptide, however, while about three-quarters do so, an endocrinopathy is rare. Production of ACTH or prolactin is usual.

image PITUITARY ADENOMAS

Pituitary adenomas must be distinguished from normal adenohypophysis, other neoplasms in the region of the pituitary fossa, and non-neoplastic masses in the region of the pituitary fossa.

Other neoplasms in the region of the pituitary fossa

image These can generally be diagnosed by conventional histology.

image Immunohistochemistry may be helpful, especially for small biopsies (see Table 44.3).

image Metastases from primary neoplasms outside the CNS are found mainly in the neurohypophysis, but can present in the adenohypophysis where their identification may be difficult (Figs 44.2344.25). It is important to distinguish carcinomas from native squamous cell nests (Fig. 44.26) that are present in approximately 30% of normal pituitaries in the pars tuberalis and hypophyseal stalk, do not disrupt the normal acinar reticulin pattern, are cytologically bland, without mitoses or pleomorphism, and often coexist with gonadotroph cells.

PITUITARY HYPERPLASIA

Pituitary hyperplasia (Table 44.4) may be nodular or diffuse. Nodular hyperplasia is characterized by enlarged cell nests and can be demonstrated in a reticulin preparation. Diffuse hyperplasia may not be obvious, requiring an appreciation of the uneven distribution of cells in the adenohypophysis (Fig. 44.28) and cell counts to make the diagnosis.

CRANIOPHARYNGIOMAS

Craniopharyngiomas are slowly-growing epithelial neoplasms in the suprasellar region, and there are two variants:

These variants have both common and differentiating histopathologic features. Transitional forms exist, but attempts should be madeto distinguish the two main variants, which have different outcomes; papillary neoplasms tend to occur in an older age group, are more readily resected, and recur less often.

The histogenesis of craniopharyngiomas is not established. Adamantinomatous neoplasms closely resemble the adamantinoma of the jaw and the calcifying odontogenic cyst. Papillary neoplasms may be related to Rathke’s cleft cyst, which can show marked squamous metaplasia.

MACROSCOPIC APPEARANCES

An admixture of cystic and solid components is characteristic (Figs 44.2944.31), and there is sometimes a smooth lobulated capsule. The solid tissue often contains foci of calcification and the cysts may contain a thick liquid that has been likened to machine oil. The papillary craniopharyngioma tends to be more circumscribed than the adamantinomatous type, and does not contain the calcification or oil-like cyst fluid of the adamantinomatous variant.

MICROSCOPIC APPEARANCES

Features of the adamantinomatous craniopharyngioma (Figs 44.3244.35) include:

Papillary craniopharyngiomas (Fig. 44.36) consist of groups of squamous cells, which may form keratin pearls. Cysts are infrequent and an adamantinomatous pattern is absent. There are no nodules of keratinized ‘ghost’ cells and calcification is rare.

The surrounding brain parenchyma is usually densely gliotic (Fig. 44.37) and may contain many Rosenthal fibers. Leakage of cyst contents may provoke an inflammatory reaction, which includes multinucleated giant cells (see Fig. 44.35).

RATHKE CLEFT CYST

Small cysts lined by cuboidal epithelium in the pars intermedia of the pituitary gland are remnants of Rathke’s pouch and can enlarge to produce a Rathke cleft cyst (Fig. 44.38). Small examples may be an incidental postmortem finding, but if the cysts are large enough they can produce endocrine or visual abnormalities.

MACROSCOPIC AND MICROSCOPIC APPEARANCES

Rathke cleft cysts usually have a thin wall and slightly cloudy mucinous contents. The cyst is lined by cuboidal or columnar epithelium, which may be ciliated (Fig. 44.38), and usually contains goblet cells. Peptide-containing cells may occasionally be found in the epithelium. The cuboidal/columnar epithelium sometimes incorporates a metaplastic stratified squamous epithelium. Microscopic cysts with a similar appearance are occasionally found in pituitary adenomas.

GRANULAR CELL NEOPLASM OF THE INFUNDIBULUM

Granular cells in the infundibulum or neurohypophysis are thought to be of glial origin. Symptomatic neoplasms of these cells are rare. Asymptomatic tiny groups of granular cells in this region, sometimes called choristomas or tumorlets, are more common.

REFERENCES

General reading

Asa, S.L. Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med.. 2008;132:1231–1240.

Asa, S.L., Tumors of the pituitary gland. Third series edn. Atlas of tumor pathology. Vol. 22, Washington, DC: Armed Forces Institute of Pathology 1998.

Burger, P.C., Scheithauer, B.W., Vogel, F.S. Region of the sella turcica. In: Surgical pathology of the nervous system and its coverings. Edinburgh: Churchill Livingstone; 2002:437–490.

Ellison, D.W., Perry, A., Ronseblum, M., et al, Pituitary and sellar tumors. 8th ed,. Love, S., Louis, D.N., Ellison, D., eds. Greenfield’s neuropathology. Vol. 2. London: Hodder Arnold; 2008:2088–2116.

Lloyd, R.V., Kovacs, K., Young, W.F., Jr., et al. Tumors of the Pituitary. In: DeLellis R.A., Lloyd R.V., Heitz P.U., et al, eds. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004:9–45.

Adenomas

Calle-Rodrigue, R.D., Giannini, C., Scheithauer, B.W., et al. Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc.. 1998;73:1046–1052.

Horvath, E., Kovacs, K. Pathology of acromegaly. Neuroendocrinology.. 2006;83(3–4):161–165.

Horvath, E., Kovacs, K., Scheithauer, B.W. Pituitary hyperplasia. Pituitary.. 1999;1:169–179.

Horvath, E. Ultrastructural markers in the pathologic diagnosis of pituitary adenomas. Ultrastruct Pathol.. 1994;18:171–179.

Keil, M.F., Stratakis, C.A. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother.. 2008;8:563–574.

Korbonits, M., Carlsen, E. Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res.. 2009;71:S123–S130.

Osamura, R.Y., Egashira, N., Kajiya, H., et al. Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution. Acta Histochem Cytochem.. 2009;42:95–104.

Osamura, R.Y., Kajiya, H., Takei, M., et al. Pathology of the human pituitary adenomas. Histochem Cell Biol.. 2008;130:495–507.

Scheithauer, B.W., Horvath, E., Kovacs, K., et al. Plurihormonal pituitary adenomas. Semin Diagn Pathol.. 1986;3:69–82.

Scheithauer, B.W., Kovacs, K.T., Laws, E.R., Jr., et al. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg.. 1986;65:733–744.

Terada, T., Kovacs, K., Stefaneanu, L., et al. Incidence, pathology, and recurrence of pituitary adenomas: study of 647 unselected surgical cases. Endocr Pathol.. 1995;6:301–310.

Thapar, K., Kovacs, K., Scheithauer, B.W., et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery.. 1996;38:99–106.

Saeger, W., Lüdecke, D.K., Buchfelder, M., et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol.. 2007;156:203–216.

Sansur, C.A., Oldfield, E.H. Pituitary carcinoma. Semin Oncol.. 2010;37:591–593.

Syro, L.V., Ortiz, L.D., Scheithauer, B.W., et al. Treatment of pituitary neoplasms with temozolomide: A review. Cancer.. 2011;117:454–462.

Zada, G., Woodmansee, W.W., Ramkissoon, S., et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg.. 2010;114:336–344.

Miscellaneous sellar/suprasellar tumors

Albright, A.L., Price, R.A., Guthkelch, A.N. Diencephalic gliomas of children. A clinicopathologic study. Cancer.. 1985;55:2789–2793.

Branch, C.L., Jr., Laws, E.R., Jr. Metastatic tumors of the sella turcica masquerading as primary pituitary tumors. J Clin Endocrinol Metab.. 1987;65:469–474.

Coons, S.W., Rekate, H.L., Prenger, E.C., et al. The histopathology of hypothalamic hamartomas: study of 57 cases. J Neuropathol Exp Neurol.. 2007;66:131–141.

Geddes, J.F., Jansen, G.H., Robinson, S.F., et al. ‘Gangliocytomas’ of the pituitary: a heterogeneous group of lesions with differing histogenesis. Am J Surg Pathol.. 2000;24:607–613.

Louis, D.N., Ohgaki, H., Wiestler, O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol.. 2007;114:97–109.

Moshkin, O., Muller, P., Scheithauer, B.W., et al. Primary pituitary lymphoma: a histological, immunohistochemical, and ultrastructural study with literature review. Endocr Pathol.. 2009;20:46–49.

Phillips, J.J., Misra, A., Feuerstein, B.G., et al. Pituicytoma: characterization of a unique neoplasm by histology, immunohistochemistry, ultrastructure, and array-based comparative genomic hybridization. Arch Pathol Lab Med.. 2010;134:1063–1069.

Roncaroli, F., Scheithauer, B.W., Cenacchi, G., et al. ‘Spindle cell oncocytoma’ of the adenohypophysis: a tumor of folliculostellate cells? Am J Surg Pathol.. 2002;26:1048–1055.

Sautner, D., Saeger, W., Ludecke, D.K. Tumors of the sellar region mimicking pituitary adenomas. Exp Clin Endocrinol.. 1993;101:283–289.

Non-neoplastic disease

Bills, D.C., Meyer, F.B., Laws, E.R., Jr., et al. A retrospective analysis of pituitary apoplexy. Neurosurgery.. 1993;33:602–608.

Flanagan, D.E., Ibrahim, A.E., Ellison, D.W., et al. Inflammatory hypophysitis – the spectrum of disease. Acta Neurochir (Wien).. 2002;144:47–56.

Paulus, W., Honegger, J., Keyvani, K., et al. Xanthogranuloma of the sellar region: a clinicopathological entity different from adamantinomatous craniopharyngioma. Acta Neuropathol.. 1999;97:377–382.

Rivera, J.A. Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary.. 2006;9:35–45.

Scanarini, M., d’Avella, D., Rotilio, A., et al. Giant-cell granulomatous hypophysitis: a distinct clinicopathological entity. J Neurosurg.. 1989;71:681–686.

Semple, P.L., De Villiers, J.C., Bowen, R.M., et al. Pituitary apoplexy: do histological features influence the clinical presentation and outcome? J Neurosurg.. 2006;104:931–937.